亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Abstract 5436: HH2853 is a selective small molecular dual inhibitor of EZH1/2 with potent anti-tumor activities

PRC2 EZH2型 组蛋白H3 生物 组蛋白甲基转移酶 癌症研究 甲基转移酶 甲基化 化学 细胞生物学 遗传学 基因
作者
Xuxing Chen,Qianqian Shen,Zhao Zhao,Yan-fen Fang,Jian Yang,Yijun Gao,Lei Liu,Yixiang Zhang,Yi Chen,Leping Li
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (12_Supplement): 5436-5436 被引量:4
标识
DOI:10.1158/1538-7445.am2022-5436
摘要

Abstract Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of lysine 27 on histone H3 (H3K27), and the histone methyltransferases EZH1/2 are the catalytic subunit of PRC2. Aberrant activation of EZH2 drives H3K27 methylation and plays a critical role in cancer initiation and progression. Meanwhile, loss-of-function mutation in the major components of SWI/SNF complex leads to a loss of its suppression ability against PRC2 and subsequently activates EZH2. Targeting EZH2 has been validated as a promising therapeutic strategy for cancer treatment, especially for those with EZH2 gain-of-function (GOF) mutations or alterations of SWI/SNF complex proteins that act as oncogenic drivers. Although when PRC2 was suppressed by EZH2 inhibition, the activity of EZH1 complementarily increased to replace the role of EZH2 and maintained the function of PRC2. In addition, EZH2 inhibition in hematopoietic stem cells of mice has been shown to facilitate the development of heterogeneous hematologic malignancies in an EZH1-dependent manner. As a result, dual inhibition of EZH1 and EZH2 may be more effective than EZH2 inhibition alone in suppressing PRC2 function, as well as overcoming the issues related to the development of secondary malignancies, which has been observed in the clinical development of EZH2 selective inhibitor. Thus, we discovered and developed HH2853,a dual inhibitor of EZH1/2. The potency and selectivity of HH2853 against EZH1/2 were assessed at biochemical and cellular levels, and its anti-tumor activities were evaluated in multiple tumor models in vitro and in vivo in comparison with FDA-approved EZH2 selective inhibitor tazemetostat. In addition, the pharmacokinetic (PK) profile of HH2853 was characterized. HH2853 inhibited the enzymatic activities of wild-type and mutant EZH2 with IC50 values of 2.21-5.36 nM, which was similar to that of tazemetostat. In addition, HH2853 inhibited EZH1 enzymatic activity with an IC50 of 9.26 nM, which was stronger than tazemetostat (IC50: 58.43 nM). In contrast, HH2853 up to 10 μM exhibited only marginal or minor inhibitory activity against 36 histone modification enzymes. At cellular level, HH2853 potently inhibited H3K27 mono-, di- and tri-methylation in multiple cancer cell lines with wild-type or mutant EZH2. In contrast, HH2853 up to 10 μM had no effect on the other types of methylation modifications on histone H3. Moreover, HH2853 potently inhibited the cell viability of multiple cancer cell lines with EZH2 GOF mutation or alterations in SWI/SNF complex, and exhibited superior anti-tumor efficacy in several tumor xenograft models than tazemetostat at a comparable dose level. Furthermore, HH2853 exhibited superior PK property than tazemetostat. Taken together, HH2853 is a selective EZH1/2 dual inhibitor with potent anti-tumor activities and favorable PK properties. HH2853 is currently in phase I clinical development. Citation Format: Xu-Xing Chen, Qian-Qian Shen, Zhao Zhao, Yan-Fen Fang, Jun-Yu Yang, Ying-Lei Gao, Lei Liu, Yixiang Zhang, Yi Chen, Leping Li. HH2853 is a selective small molecular dual inhibitor of EZH1/2 with potent anti-tumor activities [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5436.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大模型应助Yyy采纳,获得10
11秒前
Hello应助11采纳,获得10
30秒前
37秒前
hzc应助科研通管家采纳,获得10
42秒前
夏天无完成签到,获得积分10
51秒前
夏天无发布了新的文献求助10
56秒前
1分钟前
plusweng完成签到 ,获得积分10
1分钟前
耿宇航完成签到 ,获得积分10
2分钟前
中央完成签到,获得积分10
2分钟前
乐乱完成签到 ,获得积分10
3分钟前
CodeCraft应助XL神放采纳,获得10
3分钟前
xiaozang完成签到 ,获得积分10
4分钟前
所所应助yzr01采纳,获得10
4分钟前
4分钟前
4分钟前
yzr01发布了新的文献求助10
4分钟前
程风破浪发布了新的文献求助10
4分钟前
暗号完成签到 ,获得积分10
4分钟前
充电宝应助程风破浪采纳,获得10
5分钟前
5分钟前
XL神放发布了新的文献求助10
5分钟前
6分钟前
YYYY完成签到 ,获得积分10
7分钟前
7分钟前
7分钟前
程风破浪发布了新的文献求助10
7分钟前
咯咯咯发布了新的文献求助20
7分钟前
7分钟前
超级雅霜发布了新的文献求助10
7分钟前
陶醉的烤鸡完成签到 ,获得积分10
8分钟前
8分钟前
科研通AI2S应助程风破浪采纳,获得10
8分钟前
细心怜寒发布了新的文献求助10
8分钟前
美好乐松应助乐生采纳,获得10
8分钟前
哇咔咔完成签到 ,获得积分10
8分钟前
8分钟前
cc完成签到 ,获得积分10
8分钟前
8分钟前
宣灵薇完成签到,获得积分0
8分钟前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
XAFS for Everyone (2nd Edition) 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3133930
求助须知:如何正确求助?哪些是违规求助? 2784834
关于积分的说明 7768641
捐赠科研通 2440188
什么是DOI,文献DOI怎么找? 1297291
科研通“疑难数据库(出版商)”最低求助积分说明 624911
版权声明 600791